Medical Device and Healthcare Industry Trends — 2026-06-01

Top 5 Headlines Today

• Samsung Electronics to unveil an AI-based connected care ecosystem and new Samsung Health features at VivaTech 2026 (Paris, June 17-20).

• KOSDAQ Tier System: Medical device companies like Classys receive favorable assessments, while drug developers face relative pressure.

• Lunit expands its subscription-based AI business in the U.S., surpassing 930,000 cumulative SaaS contracts.

• Classys posts Q1 revenue of 87.2 billion KRW (+13% YoY), driven by the acquisition of Brazilian distributor MedSystems.

• FDA eases regulations for AI-based Clinical Decision Support (CDS) software and wearables, reducing oversight for low-risk medical devices.

Key Corporate Trends

Samsung Electronics

• What's happening: Unveiling an AI-based connected care ecosystem and new Samsung Health features at VivaTech 2026 (Paris, June 17-20).
• Key numbers: Participating in Europe’s largest tech show; expanding multiple wellness partnerships.
• Implication: Samsung’s push into AI healthcare starts with consumer wearables but is scaling into a global medical device ecosystem. Korean manufacturers should benchmark this ecosystem-based business model.

Lunit

• What's happening: Expanding its SaaS AI medical device business in the U.S. and identifying M&A opportunities in digital pathology.
• Key numbers: 930,000 cumulative SaaS contracts; leveraging global digital pathology M&A trends.
• Implication: Lunit is establishing a system-integration model for U.S. hospitals and diagnostic centers via its API-based AI diagnostic platform, serving as a notable case study for Korean AI medical device firms entering the U.S.

Classys

• What's happening: Q1 results show 13% revenue growth (YoY); finalized acquisition of Brazilian distributor MedSystems.
• Key numbers: Q1 revenue of 87.2 billion KRW; operating margin of 42.7%; revenue boost from acquisition.
• Implication: Strengthening entry into emerging markets by securing local distribution networks. A clear example of how overseas M&A can drive performance for export-oriented medical device firms.

Korean Medical Device Industry

• What's happening: KOSDAQ tier system reform boosts the relative status of medical device companies over drug developers.
• Key numbers: Split into Premium and Standard tiers; introduction of a system favorable to device firms.
• Implication: The reform signals improved funding conditions and normalized evaluation criteria for medical device firms. Unlike pharma/biotech, medical devices face fewer clinical burdens and more transparent regulatory processes.

Regulatory and Policy Updates

Repeal of Grace Period for Sales Suspension after GMP Expiration

• Details: The special "grace period" for sales suspension following a failure in the regular GMP inspection for medical device manufacturing facilities has been abolished.
• Target: All medical device manufacturers.
• Effective Date: March 26, 2026 (currently in effect).
• Industry Impact: The urgency for GMP compliance is higher; manufacturers must prepare thoroughly for renewal before the expiration date to avoid supply chain disruptions.

Revised Guidelines for Medical Device Software (SaMD) Approval

• Details: MFDS has updated approval and review standards for medical device software and AI-based devices.
• Target: SaMD, AI diagnostic software, and Digital Therapeutics (DTx).
• Industry Impact: Clearer guidelines may shorten review times for companies like Lunit and Vuno, though clinical evidence requirements may tighten.

Digital Health and AI Medicine

• FDA Regulatory Relief (U.S.): As of January 2026, the FDA reduced oversight for low-risk CDS software and wellness wearables, lowering entry barriers for Korean wellness companies like Samsung and LG.

• Samsung Health Ecosystem: The platform is evolving into an integrated screening and monitoring service based on wearable data.

• Digital Health Investment: Despite a global VC slowdown, companies with approved DTx and SaMD are seeing strong late-stage funding.

Global MedTech Context

• FDA Regulatory Easing: The move benefits Korean wearable brands like Samsung and LG, facilitating easier entry into the U.S. market for consumer-oriented health devices.

• Global Digital Pathology M&A: Korean AI firms are seeking integration with hospital systems in the U.S. and Europe, amid active M&A by giants like Roche and Abbott.

• FDA TEMPO Pilot Program: The "Technology-Enabled Patient-Focused Medical Device" pilot launched in December 2025 aims to accelerate market entry for chronic disease monitoring devices.

Investment and M&A

• Classys/MedSystems: Successful acquisition highlights the importance of securing South American distribution.
• Lunit/SaaS: Reaching 930,000 contracts is a key KPI for future funding and IPO preparations.

Insights

Samsung’s participation in VivaTech signals a major push by Korean conglomerates into global medical markets. Meanwhile, FDA regulatory easing creates a wider door for Korean startups and wearable manufacturers. The KOSDAQ tier reform will likely lead to a re-rating of companies like Classys. While tighter MFDS GMP regulations increase compliance costs, they ultimately favor firms with higher product competitiveness.

This Week's Checkpoints

• Samsung’s AI Healthcare ecosystem launch at VivaTech 2026 (June 17-20).
• Trends in MFDS innovative medical device designations and fast-track usage.
• Overseas clinical progress and U.S. expansion news for firms like Lunit and Vuno.

Reader Action Items

• Professionals: Audit your GMP inspection schedule to ensure compliance and avoid sales suspensions.
• Investors: Track the valuation changes of medical device stocks (Classys, Osstem Implant, etc.) under the new KOSDAQ tier system.
• Founders: Review the latest FDA guidelines on low-risk AI and wellness wearables for potential U.S. market entry strategies.